Genenta Science (NASDAQ: GNTA) CMO granted stock options on 20,000 ADS

Q: What insider transaction did GNTA executive Francesco Galimi report on this Form 4?

Francesco Galimi reported receiving a grant of stock options for 20,000 American Depositary Shares . These options are a compensation-related award, not an open-market trade, and give him the right to buy GNTA ADS at a preset exercise price.

Q: What is the exercise price and term of the new GNTA stock options granted to Francesco Galimi?

The granted stock options have an exercise price of $0.63 per share and an expiration date of December 31, 2035 . This means Galimi can choose to purchase GNTA American Depositary Shares at $0.63 any time before they expire.

Q: How many GNTA derivative securities does Francesco Galimi hold after this Form 4 transaction?

After this transaction, Galimi holds 20,000 stock options covering 20,000 American Depositary Shares , all reported as directly owned. This filing does not show additional derivative positions, so this grant represents his visible option holdings here.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Genenta Science S.p.A. reported that its CMO & Head of Development, Francesco Galimi, received a grant of stock options covering 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.

The options vest in equal monthly installments over one year beginning March 30, 2026. Following this grant, Galimi holds stock options for 20,000 ADS directly, reflecting a compensation-related award rather than an open-market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Galimi Francesco

Role CMO& Head of Development

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Options granted: 20,000 options Exercise price: $0.63 per share Expiration date: December 31, 2035 +2 more

5 metrics

Options granted 20,000 options Covering 20,000 American Depositary Shares

Exercise price $0.63 per share Stock option exercise price

Expiration date December 31, 2035 Option term end

Vesting start March 30, 2026 Monthly vesting over one year

Holdings after grant 20,000 options Total stock options following transaction

Key Terms

Stock Option (right to buy), American Depositary Shares, exercise price, vest in equal monthly installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

American Depositary Shares financial

"underlying_security_title: American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exercise price financial

"conversion_or_exercise_price: 0.6300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"The stock options vest in equal monthly installments over one year"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galimi Francesco

(Last)

(First)

(Middle)

12930 VIA ESPERIA

(Street)

DEL MAR

CALIFORNIA

92014

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genenta Science S.p.A. [ GNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CMO& Head of Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.63	03/30/2026		A		20,000		⁽¹⁾	12/31/2035	American Depositary Shares	20,000	$0	20,000	D

Explanation of Responses:

1. The stock options vest in equal monthly installments over one year beginning March 30, 2026.

	/s/ Francesco Galimi	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did GNTA executive Francesco Galimi report on this Form 4?

Francesco Galimi reported receiving a grant of stock options for 20,000 American Depositary Shares. These options are a compensation-related award, not an open-market trade, and give him the right to buy GNTA ADS at a preset exercise price.

What is the exercise price and term of the new GNTA stock options granted to Francesco Galimi?

The granted stock options have an exercise price of $0.63 per share and an expiration date of December 31, 2035. This means Galimi can choose to purchase GNTA American Depositary Shares at $0.63 any time before they expire.

How do the newly granted GNTA stock options to Francesco Galimi vest?

The stock options vest in equal monthly installments over one year, starting on March 30, 2026. Monthly vesting spreads the award over 12 months, so Galimi gradually earns the right to exercise more options during that period.

How many GNTA derivative securities does Francesco Galimi hold after this Form 4 transaction?

After this transaction, Galimi holds 20,000 stock options covering 20,000 American Depositary Shares, all reported as directly owned. This filing does not show additional derivative positions, so this grant represents his visible option holdings here.

Was the GNTA Form 4 transaction a purchase or sale of shares on the open market?

No, this Form 4 does not show an open-market purchase or sale. It reports a grant/award acquisition of stock options to Galimi as part of compensation, with no cash purchase or sale of GNTA shares disclosed in the transaction data.